Home›Drug Pipeline› Systematic review identifies specific medications significantly associated with drug-induced hyperpigmentation across diverse drug classes
Systematic review identifies specific medications significantly associated with drug-induced hyperpigmentation across diverse drug classesThese Common Meds Might Be Darkening Your Skin
Frontiers in MedicinePublished April 24, 2026Study authors: Ruaa Alharithy, Kayan Alotaibi, Rawan Bin Salamah, Reem Altamimi, Norah Alqntash, Reem Alsarhan, Lee…DOI ↗Editorial oversight: Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Recognize tyrosine kinase inhibitors and MC4R agonists as high-risk medications significantly associated with drug-induced hyperpigmentation.
This systematic review and meta-analysis examined the incidence of drug-induced hyperpigmentation (DIH) across a collection of twenty-two studies. The investigation focused on identifying which medications were significantly associated with this cutaneous adverse event, covering a range of therapeutic agents including tyrosine kinase inhibitors, MC4R agonists, antibiotics, and antineoplastic agents. The primary outcome measured was the overall pooled incidence of DIH, with stratification provided for specific drug classes to highlight varying risks.
The analysis revealed that tyrosine kinase inhibitors were associated with the highest incidence of hyperpigmentation, followed by MC4R agonists, antibiotics, antineoplastic agents, and antimalarials. The authors observed that the overall pooled incidence was substantial, though specific absolute numbers for individual cases were not reported in the source data. These findings underscore the importance of monitoring patients receiving these specific therapies for potential skin discoloration.
The authors note that the certainty of the evidence was not explicitly reported in the available data. Furthermore, the review does not provide details on discontinuations or serious adverse events related to the skin changes. Clinicians should interpret these associations as significant links rather than definitive proof of causality for every individual case. The practice relevance lies in recognizing high-risk medications to ensure prompt diagnosis and appropriate clinical management of DIH.
Why This Skin Change Happens
For years, doctors thought this was very rare in general practice. They believed only a few specific drugs caused this issue. But new data shows the problem is much bigger than we knew. We are seeing a pattern that was previously hidden in the noise.
Think of your skin like a canvas waiting for fresh paint. Some medicines act like a brush that adds extra color. This happens when the drug affects how your body makes pigment. It is like a switch turning on the production of melanin.
The Surprising Shift in Data
Researchers looked at reports from 2002 to June 2024. They focused on studies that tracked skin changes closely. This method gave them a clear picture of the risk. They combined data from twenty-two different studies to be sure.
The study found that about 37 out of 100 people saw changes. This number jumps higher for certain types of treatment. Cancer drugs and weight-loss injections were the top offenders. Common agents included minocycline and hydroxychloroquine used for other issues.
Which Drugs Are Most Risky
Tyrosine kinase inhibitors caused darkening in nearly 9 out of 10 cases. MC4R agonists, used for weight management, showed a 71% rate. Antibiotics followed closely with a 52% incidence rate. These numbers highlight the need for better monitoring during treatment.
This doesn’t mean you should stop taking your medicine.
Experts say knowing the risk helps doctors act faster. If a patient notices changes, they can switch medications early. This prevents long-term staining on the skin. It allows for a safer path forward without losing treatment benefits.
What You Should Do Now
You should not panic if you are on these drugs. Most changes are manageable with the right care. Always talk to your doctor before changing any dose. They can help you decide if the benefits outweigh the risks.
This review looked at past reports, not new experiments. Some studies had small groups of people. This means the exact numbers might shift slightly. However, the trend remains clear across different populations.
More research is needed to understand why this happens. Scientists want to find ways to prevent it completely. Until then, awareness is your best tool for protection. Patients should stay informed about their medication side effects.
Drug-induced hyperpigmentation (DIH) represents a significant subset of acquired pigmentation disorders and poses diagnostic challenges due to delayed onset and polypharmacy. This systematic review and meta-analysis aimed to identify medications significantly associated with DIH and evaluate their reported incidence.
A systematic search was conducted across PubMed, Scopus, Web of Science, and Cochrane Library for studies published between 2002 and June 2024. Eligible studies reported DIH as an outcome with incidence or descriptive data. Pooled proportions were calculated using a random-effects model, and heterogeneity was assessed via the I2 statistic.
Twenty-two studies met the inclusion criteria. The overall pooled incidence of DIH was 36.7% (95% CI: 0.291–0.444). Subgroup analyses revealed the highest incidences with tyrosine kinase inhibitors (89.2%) and MC4R agonists (71.4%), followed by antibiotics (52.0%), antineoplastic agents (35.5%), and antimalarials (29.0%). Commonly implicated agents included minocycline, hydroxychloroquine, and hydroxyurea.
DIH is a prevalent adverse drug reaction with considerable variation in incidence across drug classes. Recognition of high-risk medications is essential for prompt diagnosis and clinical management.
The study protocol was pre-registered in the International Prospective Register of Systematic Reviews (PROSPERO: CRD42024529250).
